- India's Supreme Court blocks Mumbai-based Glenmark Pharmaceuticals Ltd. from selling generic versions of Merck's (NYSE:MRK) diabetes drugs Januvia and Janumet, although Glenmark will be able to sell its existing inventory.
- Merck sued Glenmark in 2013 for infringing on a patent covering sitagliptin, the active ingredient in its two drugs.
Merck wins Januvia patent case in India
Recommended For You
About MRK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MRK | - | - |
| Merck & Co., Inc. | ||